Intradermal influenza vaccine
AssigneeCrucell Switzerland AG
InventorsChristian Herzog, Hedvika Lazar
Life of this patent
Estimating the term…
Abstract
The invention relates to virosome-based influenza vaccines for the manufacture of medicaments that are administered intradermally in humans. The invention provides (trivalent) compositions comprising low doses of hemagglutinin (HA) antigen in a virosomal preparation that fulfill the immune response standards with respect to seroconversion rates, GMT-fold increase and protection rates, for use in vaccination set-ups.
Claims23
A virosomal preparation comprising influenza hemagglutinin (HA) antigen, for use as an intradermal influenza vaccine in human subjects.
A method of vaccinating a subject against influenza, wherein the improvement comprises:
- intradermally administering a virosomal preparation comprising influenza hemagglutinin (HA) antigen to a human subject.
A kit comprising:
- a) a virosomal preparation comprising influenza hemagglutinin (HA) antigen for vaccination of human subjects against influenza, wherein the preparation does not contain an additional adjuvant and wherein the preparation does not contain antigens from viruses other than influenza virus;
- and
- b) a delivery device suitable for intradermal delivery of vaccines.
A method of vaccinating a human subject against influenza infections, said method comprising administering intradermally to the human subject a virosomal preparation comprising influenza hemagglutinin (HA) without additional adjuvant.
A method of vaccinating a mammalian subject against influenza infection, said method comprising the steps of:
- preparing a trivalent virosome-based influenza vaccine comprising hemagglutinin (HA) antigen from three influenza strains without additional adjuvant;
- and
- administering said vaccine to the mammalian subject intradermally.
Dependencies are inferred from the claim text.